Search academic texts

Information × Registration Number 0206U000959, 0103U007499 , R & D reports Title New molecular-genetic methods for diagnostics in breast cancer patients based on monitoring of their cytokine status and expression of specific cellular markers popup.stage_title Head Stoyka Rostyslav Stepanovych, Доктор біологічних наук Registration Date 09-02-2006 Organization Institute of cell biology, National Academy of Sciences of Ukraine popup.description2 Inclusion of recombinant interferon (rIFN) in the traditional charts of treatment of patients with breast cancer substantially improves clinical indexes, which correlates with data of biochemical analysis and immunohistochemical researches of tumour material. The two-year looking after patients, conducted by us, witnessed that 91% of patients of experimental group, who received the rIFN, were in the state of remission, while in the control group only 66% of them were in state of remission, and one patient died. Looking after these groups of patients continues. Generalization of research results of TGF-beta activity level dynamics in the blood serum of all treated BC patients testifies the correlation between direction of changes of TGF-beta activity in the blood serum of considerable part of the analyzed patients and nature of disease motion after the conducted treatment. The trustworthy lowering of proliferative activity of tumor cells was in the group of patients with BC, who were treated with rIFNas a part of complex therapy. It was confirmed by the lowering of of PCNA antigen level of expression and proliferation index. The obtained data testify the expedience of inclusion of rIFN in the complex charts of treatment of patients with BC, and also possibility of utilizing monitoring of level of explored cytokines and specific cellular markers for diagnostics, prognosis of disease motion estimation of efficiency of anti-cancer therapy. Product Description popup.authors popup.nrat_date 2020-04-02 Close